{"id":"W4405042974","doi":"10.1182/blood-2024-203269","title":"First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Adverse effect; Internal medicine; Oncology; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001277745,0.0009910018,0.001973056,0.00105167,0.0003088294,0.0002212318,0.001150459,0.0004164761,0.0002901688],"category_scores_gemma":[0.0009266023,0.0007264441,0.0004323311,0.003578541,0.0004029404,0.0003733053,0.001221314,0.0008745617,0.00007749693],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1871344,"about_ca_system_score_gemma":0.09270419,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0150276,"about_ca_topic_score_gemma":0.06272344,"domain_scores_codex":[0.9917466,0.0003212236,0.001394491,0.001961812,0.002938564,0.001637324],"domain_scores_gemma":[0.9949071,0.0006906299,0.0002979967,0.002923894,0.0003703684,0.0008099779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.1911859,0.01450431,0.2080986,0.03303942,0.06780931,0.1352208,0.03759512,0.2112375,0.0001813542,0.0003198716,0.009725919,0.09108189],"study_design_scores_gemma":[0.43026,0.01894929,0.02367341,0.003202258,0.008759809,0.0004649847,0.00106142,0.5101348,0.000282624,0.00004872779,0.001772842,0.001389863],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892933,0.004341875,0.00007763966,0.0000950942,0.0004768153,0.004857959,0.0001758465,0.0003672752,0.0003141701],"genre_scores_gemma":[0.9956648,0.0006105796,0.000306109,0.00004762792,0.0004221276,0.0007485586,0.0002893818,0.0002046507,0.001706148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2988973,"threshold_uncertainty_score":0.9995187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01900988019883937,"score_gpt":0.2961543045955663,"score_spread":0.2771444243967269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}